论文部分内容阅读
目的探究氯吡格雷预防冠心病介入治疗心血管的临床疗效。方法 70例冠心病介入治疗心血管疾病的患者,将其随机分为对照组(33例)和研究组(37例)。对照组行噻氯匹定治疗,研究组行氯吡格雷治疗,对比两组临床治疗效果。结果两组患者的术后凝血酶原时间、凝血酶时间以及纤维蛋白原等凝血功能指标比较,差异无统计学意义(P>0.05),对照组患者术后不良反应发生率为21.2%,明显高于研究组患者术后不良反应发生率6.4%(P<0.05)。结论氯吡格雷预防冠心病介入治疗心血管,对凝血功能无影响,利于降低术后不良反应发生率,可以推广应用。
Objective To investigate the clinical effect of clopidogrel in the prevention of cardiovascular interventional therapy by coronary heart disease. Methods Seventy patients with coronary artery disease who were involved in the treatment of cardiovascular diseases were randomly divided into control group (33 cases) and study group (37 cases). The control group was treated with ticlopidine, and the study group received clopidogrel. The clinical effects of the two groups were compared. Results There was no significant difference in postoperative prothrombin time, thrombin time and fibrinogen and other coagulation parameters between the two groups (P> 0.05). The incidence of postoperative adverse reactions in the control group was 21.2% Higher than the study group patients postoperative adverse reaction rate of 6.4% (P <0.05). Conclusion Clopidogrel prevents coronary artery disease interventional treatment of cardiovascular, coagulation has no effect, which will help reduce the incidence of postoperative adverse reactions, can be extended.